Watson to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference

PARSIPPANY, N.J., June 1, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2011 Goldman Sachs 32nd Annual Global Healthcare Conference on Wednesday, June 8, 2011 at 11:00am Eastern Time at the Terranea Resort in Rancho Palos Verdes, California. The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Website at http://ir.watson.com.  The webcast can also be accessed at the following URL:

http://cc.talkpoint.com/gold006/060711a_lr/?entity=4_BHJFWWH

An archived version will be available for 30 days after the live presentation and can be accessed at the same locations.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

(Logo:  http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )

CONTACTS:

Investors:


Patty Eisenhaur


(862) 261-8141




Media:


Charlie Mayr


(862) 261-8030



SOURCE Watson Pharmaceuticals, Inc.

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.